Typicality: | 0.343 |
Saliency: | 0.219 |
with the us department of defense | 6 | other |
further | 3 | manner |
between dr. david heckerman | 2 | other |
vaccine → be developed in → collaboration | 7 |
vaccine → be developed in → partnership | 5 |
vaccine → be developed through → partnership | 3 |
negative | neutral | positive |
0.017 | 0.748 | 0.235 |
Raw frequency | 15 |
Normalized frequency | 0.219 |
Modifier score | 0.500 |
Perplexity | 140.404 |